BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-40@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. — TQB2
 102 for Injection [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Clinical Trial of TQB2102 for Inj
 ection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast
  Cancer.\nSource: https://clinicaltrials.gov/study/NCT06561607\nhttps://ca
 talystbrief.girapphe.com/e/40?lang=en\nNot investment advice. Dates may ch
 ange.
URL:https://catalystbrief.girapphe.com/e/40?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
